Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Random

Display 45 Products per page

Zeltherva
Read More
Zeltherva’s (galinpepimut-S; SELLAS Life Sciences Group) larger target patient population gives it more commercial potential than other drugs being positioned towards the maintenance setting.
July 6, 2017
Find out more
Cenicriviroc
Read More
Cenicriviroc (Allergan/Takeda) is a potent immunomodulator that blocks the chemokine receptors-2/5 (CCR-2/5). CCR-2/5 have been linked to the inflammatory and fibrogenic pathways in non-alcoholic steatohepatitis (NASH), and by inhibiting CCR-2/5 it is anticipated that cenicriviroc will reduce inflammation and fibrosis.
July 22, 2019
Find out more
Empliciti
Read More
Empliciti is a MAb that targets the signaling lymphocytic activation molecule family, member 7 (SLAMF7), also called CS1.
August 9, 2018
Find out more
Avastin
Read More
Avastin (bevacizumab; Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).
February 26, 2020
Find out more
Gilotrif
Read More
Gilotrif is an orally administered TKI that irreversibly binds to EGFR/human epidermal growth factor receptor 1 (HER1), HER2, and HER4.
August 30, 2018
Find out more
Synagis
Read More
Synagis (palivizumab; AstraZeneca/AbbVie) is the global standard of care for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.
October 5, 2018
Find out more
Encorafenib
Read More
Encorafenib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is a RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E.
May 23, 2018
Find out more
Abilify/Abilify Maintena
Read More
Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A receptor.
March 29, 2019
Find out more
Apleway
Read More
Apleway (tofogliflozin; Chugai) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.
November 7, 2017
Find out more
Remicade
Read More
Remicade (infliximab; Johnson & Johnson/Merck & Co/Mitsubishi Tanabe) is a chimeric, humanized monoclonal antibody targeting tumor necrosis factor (TNF)-alpha, with a long history of use in a number of immune-mediated inflammatory diseases, including Crohn’s disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Behçet’s syndrome, and ulcerative colitis.
August 2, 2018
Find out more
Entrectinib
Read More
Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.
August 30, 2018
Find out more
Fetzima
Read More
Fetzima (levomilnacipran; Allergan) is a serotonin-norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in the US.
March 29, 2019
Find out more
Risperdal Consta
Read More
Risperdal Consta (Johnson & Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors.
April 9, 2018
Find out more
Triumeq
Read More
Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
June 28, 2019
Find out more
Ganaxolone
Read More
Marinus Pharmaceuticals is developing ganaxolone, a first-in-class synthetic neurosteroid drug for the adjunctive treatment of status epilepticus and pediatric orphan indications.
May 23, 2017
Find out more
Dacomitinib
Read More
Dacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including…
August 30, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *